Small Cap Feast
Small Cap Feast – 25 March 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
Laura Ashley has left the main market following the appointment of administrators.
Laura Ashley has left the main market following the appointment of administrators.
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
DRI Healthcare—investment company focused on investments in healthcare Royalty Assets looking to raise $350m. Timetable now extended.
Shearwater Group 209p £46.2m (SWG.L)
The organisational resilience group, provides an update in relation to measures taken by the Company in response to COVID-19 and on trading during March 2020.
The significant majority of Shearwater’s employees and customers are now working remotely.
Following extensive stress-testing of its network access, everyday business tools and applications, the Group confirms that it is operating effectively and providing its services to its customers without interruption.
During March 2020, the universally substantial increase in remote working has resulted in group company SecurEnvoy experiencing an increase in demand for its security software products and this increased level of interest has resulted in a number of new contract wins and existing contract upgrades for its SecurIdentity MFA multi-factor authentication ( “MFA”) software solution.
The Company is greatly encouraged by the increased interest in its software products and has yet to see any significant impact on profitability or cash flow as a result of COVID-19. The Group looks forward to updating shareholders in a planned trading update during April 2020.
Silence Therapeutics 497p £390m (SLN.L)
R&D Update. This follows today’s announcement that the Company will receive a $60m cash payment and a further $20m equity investment from AstraZeneca.
Due to the significant strengthening of the Company’s balance sheet, the Board has taken the decision to accelerate SLN360, an Lp(a) targeting siRNA for the potential treatment of cardiovascular disease. The asset has been re-allocated as Silence’s highest priority development programme as a result of the high and prevalent unmet medical need and the excellent preclinical profile. The Company intends to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) later this year and thereafter commence a first in man study with a view to generating interim data around the middle of 2021.
For SLN124, in view of the COVID-19 outbreak and to ensure the integrity of safety monitoring procedures for patients, Silence Has decided to pause patient recruitment under the current protocol.
Blackbird 9.5p £31.9m (BIRD.L)
The developer and seller of the market-leading cloud video editing platform, announced today that A+E Networks® will double the volume edited through the Blackbird platform to both enable a significant expansion of remote video production capability, while ensuring the overall safety of its editors who will now be able to work even more effectively, remotely.
A+E Networks, a joint venture between Hearst and Disney, has a portfolio of global brands that includes A&E®, HISTORY®, Lifetime®, LMN®, fyi® and Viceland®. The international media network first incorporated Blackbird within its infrastructure for a range of key cloud video production workflows in June 2019 – delivering major productivity enhancements across its operations.
This latest expansion sees A+E Networks double the volume of file-based content available to its production teams for access through Blackbird. The visibility, immediacy and management of A+E Network’s entire video archive will be significantly accelerated for the repurposing of content. Production teams will use Blackbird to rapidly ingest, view, edit and publish content using a choice of hybrid workflows – on-premise through the Blackbird cloud as well as on the Amazon Web Services (AWS) public cloud.
Venture Life 32.5p £27.2m (VLG.L)
2020 has started well for the Group, despite the issues surrounding the COVID-19 outbreak. The Group’s business units in the UK, Italy and the Netherlands are still operational at this time. The Italian Government has closed all but essential businesses in Italy from the start of this week, but the Italian business is still allowed to operate as it is considered an essential business.
Since the start of the year, orders of Dentyl (received both before and after the COVID-19 outbreak in China and the rest of the world) have resumed from the Chinese partner, as their marketing efforts have reinvigorated demand for the product. So far this year, the Group has received orders of over €7m from this particular partner (compared to only €0.5m total sales in 2019) for Dentyl and other products, for delivery in 2020. Whilst the COVID-19 outbreak has brought uncertainty at this time, the Board is very pleased with the strong resumption of its business into China, and the resilience and strength of its business and employees that continue to operate in these difficult circumstances.
Finally, as part of the effort to combat COVID-19, the Group is manufacturing hand sanitiser gel at its facility in North Lombardy, which it is supplying free of charge on a compassionate basis to local hospitals and pharmacies.
Ramsdens Holdings 92.5p £28.5m (RFX.L)
Ramsdens, the diversified financial services provider and retailer, has noted the recent announcement by the UK Government regarding the closure of non-essential stores. As a result, effective from yesterday, the Group closed all its stores in the UK until further notice.
As stated in the Group’s trading update on 18 March 2020, Ramsdens has a strong balance sheet, including approximately £10m of cash and an undrawn £10m revolving credit facility. The Group welcomes the support measures for businesses outlined by the UK Government so far and plans to utilise those measures that are applicable to the Group. The Group will provide a further update as and when appropriate.
Peter Kenyon, CEO of Ramsdens, commented:
“The safety and wellbeing of our customers, colleagues and the wider community remains our top priority and we are doing what is best by them. We have been following Government guidance throughout this unprecedented period and, following the most recent Government instructions, yesterday we closed our shops until further notice. We look forward to once again opening our doors and serving all the local communities where we operate. Until that time, our jewellery website will remain active for our customers to browse our extensive range of new and second-hand jewellery and luxury brand watches.”
Ncondezi Energy 3.8p £12.35m (NCCL.L)
General update on its power tariff finalisation and submission process for the integrated Ncondezi 300MW coal fired power project and coal mine in Tete, Mozambique .
- Project Financial Model now in final form and awaiting final approvals from the Company’s Board of Directors and its Partners to be submitted to Electricidade de Moçambique
- Tariff submission remains on track for Q1 2020
- Proposals under review to provide additional capital to cover working capital costs beyond Q2 2020
Given the uncertainty and rapidly changing nature of the situation, Ncondezi is working to protect its cash flow by pro-actively managing its capital expenditure and working capital as well as identifying opportunities for cost savings that will not impact the long-term success of the Company.
The Company currently has adequate cash resources to cover corporate costs until Q2 2020 (subject to the shareholder loan extension). We are actively exploring a number of funding and working capital solutions beyond this period. A number of financing proposals have been received and are currently under review.
Novacyt 167.5p £113.4m (NCYT.L)
The international specialist in clinical diagnostics, announces that Primerdesign, its molecular diagnostics division, has signed a global distribution agreement for its COVID-19 test with Bruker-Hain Diagnostics, the molecular diagnostics products business unit of Bruker Corporation (Bruker).
Novacyt’s real-time polymerase chain reaction (PCR) COVID-2019 IVD-CE test is validated for use on Bruker-Hain Diagnostics’ GenoXtract® automated nucleic acid extraction device and associated extraction kits. It is under validation on Bruker’s new FluoroCycler® XT PCR instrument, allowing Bruker to provide a full solution from automated extraction to result. Bruker has already initiated shipments of the Primerdesign test into Spain, France, Germany and UK.
The Company also announces that the Republic of the Philippines Department of Health Food and Drug Administration has approved the Company’s COVID-19 test for commercial use, effective immediately.
Yourgene 17p £105m (YGEN.L)
The international molecular diagnostics group, announces the signing of an agreement for contract manufacturing services with Novacyt S.A., an international specialist in clinical diagnostics, to support the production of COVID-19 diagnostic tests developed by Primerdesign, Novacyt’s molecular diagnostics division.
Yourgene will make use of its state-of-the-art manufacturing facility at Citylabs in Manchester, UK, to work alongside Novacyt to ramp-up production of their COVID-19 test. The first batches are expected to be shipped from the Citylabs site over the next few weeks. In the interest of speed, the Company will initially manufacture critical components for Primerdesign’s COVID-19 test. The two companies may subsequently seek to expand the agreement to utilize Yourgene’s ability to produce final versions of the COVID-19 testing kits.
SIMEC AtlantisEnergy 8p £34.33m (SAE.L)
The global developer, owner and operator of sustainable energy projects, announced that MeyGen Plc has been awarded a £1.54m grant from the Scottish Government’s Saltire Tidal Energy Challenge Fund to develop a subsea tidal turbine connection hub for the next phase of development of the MeyGen tidal power array, the world’s largest tidal stream power project.
Cadence Minerals 3.225p £3.4m (KDNC.L)
Notes yesterday’s update from Macarthur Minerals (TSX-V: MMS), that it has been awarded a grant valued at $85,000 from the Western Australian Government to support drilling of a diamond drill hole at its Moonshine North Nickel Prospect, located within its Lake Giles Iron Project in Western Australia.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.